Answers are grounded in this paper and cite their sources.
In vitro study reveals varied cytotoxic activity across homodinuclear ruthenium complexes in cancer cell lines, highlighting the critical role of bridging ligand design.
Herein we report the synthesis and full characterisation of Ru(II)-based homobimetallic complexes bridged by diphosphines of the type [{(p-cym)RuCl2}2(µ-dppx)], where p-cym = η6-1-isopropyl-4-methylbenzene, dppx = dppe (1,2-bis(diphenylphosphino)ethane, 1), tdppe (trans-1,2-bis(diphenylphosphino)ethylene, 2), dppa (bis(diphenylphosphino)acetylene, 3), dcpe (1,2-bis(dicyclohexylphosphino)ethane, 4), and 1,4dppb (1,4-bis(diphenylphosphino)benzene, 5). We also report the mononuclear complexes [(p-cym)RuCl2(κ1-dppx)], where dppx = dppe (6) and tdppe (7). Complexes 2, 4, 5, 6 and 7 were further characterised via single crystal X-ray diffraction analysis. The bimetallic complexes were synthesised in a straightforward fashion and isolated in good to excellent yields. The mononuclear complexes 6 and 7 are stable in air but exhibit reactions in solution, hindering their use as precursors for the synthesis of bimetallic complexes. The in vitro cytotoxic (anticancer) activities of complexes 1–5 were determined via cell viability studies and their IC50 values were derived on HeLa and Ect1/E6E7 cell lines. All complexes displayed only low to moderate activity and selectivity. Strikingly, the cytotoxic profiles of the different complexes varied substantially, highlighting the importance of the bridging ligand itself in the cytotoxic behaviour of the complexes, further demonstrating the importance of ligand design in bimetallic complexes.
No takes yet. Share an insight, caveat, or question.
Roufosse et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: